DEUTERIUM-ENRICHED ARIPIPRAZOLE

1 . A deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 -R 27 are independently selected from H and D; and the abundance of deuterium in R 1 -R 27 is at least 4%.

2 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 -R 27 is selected from at least 4%, at least 7%, at least 15%, at least 22%, at least 30%, at least 37%, at least 44%, at least 52%, at least 59%, at least 67%, at least 74%, at least 81%, at least 89%, at least 96%, and 100%.

3 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 is 100%.

4 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 2 -R 3 is selected from at least 50% and 100%.

5 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 6 -R 8 and R 25 -R 27 is selected from at least 17%, at least 33%, at least 50%, at least 67%, at least 83%, and 100%.

6 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 and R 2 -R 3 is selected from at least 33%, at least 67%, and 100%.

17 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 , R 6 -R 8 , and R 25 -R 27 is selected from at least 14%, at least 29%, at least 43%, at least 57%, at least 71%, at least 86%, and 100%.

8 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 2 -R 3 , R 6 -R 8 , and R 25 -R 27 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.

9 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 1 , R 2 -R 3 , R 6 -R 8 , and R 25 -R 27 is selected from at least 11%, at least 22%, at least 33%, at least 44%, at least 56%, at least 67%, at least 78%, 100%.

10 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 6 -R 27 is selected from at least 5%, at least 9%, at least 14%, at least 18%, at least 23%, at least 27%, at least 32%, at least 36%, at least 41%, at least 45%, at least 50%, at least 55%, at least 59%, at least 64%, at least 68%, at least 73%, at least 77%, at least 82%, at least 86%, at least 91%, at least 95%, and 100%.

11 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 2 -R 5 is selected from at least 25%, at least 50%, at least 75%, and 100%.

12 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 9 -R 16 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.

13 . A deuterium-enriched compound of claim 1 , wherein the abundance of deuterium in R 17 -R 24 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.

14 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 1-14 of Table 1:

15 . A deuterium-enriched compound of claim 1 , wherein the compound is selected from compounds 15-28 of Table 2:

16 . An isolated deuterium-enriched compound of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 -R 27 are independently selected from H and D; and

the abundance of deuterium in R 1 -R 27 is at least 4%.

17 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 1 -R 27 is selected from at least 4%, at least 7%, at least 15%, at least 22%, at least 30%, at least 37%, at least 44%, at least 52%, at least 59%, at least 67%, at least 74%, at least 81%, at least 89%, at least 96%, and 100%.

18 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 1 is 100%.

19 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 2 -R 3 is selected from at least 50% and 100%.

20 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 6 -R 8 and R 25 -R 27 is selected from at least 17%, at least 33%, at least 50%, at least 67%, at least 83%, and 100%.

21 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 1 and R 2 -R 3 is selected from at least 33%, at least 67%, and 100%.

22 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 1 , R 6 -R 8 , and R 25 -R 27 is selected from at least 14%, at least 29%, at least 43%, at least 57%, at least 71%, at least 86%, and 100%.

23 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 2 -R 3 , R 6 -R 8 , and R 25 -R 27 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.

24 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 1 , R 2 -R 3 , R 6 -R 8 , and R 25 -R 27 is selected from at least 11%, at least 22%, at least 33%, at least 44%, at least 56%, at least 67%, at least 78%, 100%.

25 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 6 -R 27 is selected from at least 5%, at least 9%, at least 14%, at least 18%, at least 23%, at least 27%, at least 32%, at least 36%, at least 41%, at least 45%, at least 50%, at least 55%, at least 59%, at least 64%, at least 68%, at least 73%, at least 77%, at least 82%, at least 86%, at least 91%, at least 95%, and 100%.

26 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 2 -R 5 is selected from at least 25%, at least 50%, at least 75%, and 100%.

27 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 9 -R 16 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.

28 . An isolated deuterium-enriched compound of claim 16 , wherein the abundance of deuterium in R 17 -R 24 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.

29 . An isolated deuterium-enriched compound of claim 16 , wherein the compound is selected from compounds 1-14 of Table 1:

30 . An isolated deuterium-enriched compound of claim 16 , wherein the compound is selected from compounds 15-28 of Table 2:

31 . A mixture of deuterium-enriched compounds of formula I or a pharmaceutically acceptable salt thereof:

wherein R 1 -R 27 are independently selected from H and D; and

the abundance of deuterium in R 1 -R 27 is at least 4%.

32 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 1 -R 27 is selected from at least 4%, at least 7%, at least 15%, at least 22%, at least 30%, at least 37%, at least 44%, at least 52%, at least 59%, at least 67%, at least 74%, at least 81%, at least 89%, at least 96%, and 100%.

33 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 1 is 100%.

34 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 2 -R 3 is selected from at least 50% and 100%.

35 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 6 -R 8 and R 25 -R 27 is selected from at least 17%, at least 33%, at least 50%, at least 67%, at least 83%, and 100%.

36 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 1 and R 2 -R 3 is selected from at least 33%, at least 67%, and 100%.

37 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 1 , R 6 -R 8 , and R 25 -R 27 is selected from at least 14%, at least 29%, at least 43%, at least 57%, at least 71%, at least 86%, and 100%.

38 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 2 -R 3 , R 6 -R 8 , and R 25 -R 27 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.

39 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 1 , R 2 -R 3 , R 6 -R 8 , and R 25 -R 27 is selected from at least 11%, at least 22%, at least 33%, at least 44%, at least 56%, at least 67%, at least 78%, 100%.

40 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 6 -R 27 is selected from at least 5%, at least 9%, at least 14%, at least 18%, at least 23%, at least 27%, at least 32%, at least 36%, at least 41%, at least 45%, at least 50%, at least 55%, at least 59%, at least 64%, at least 68%, at least 73%, at least 77%, at least 82%, at least 86%, at least 91%, at least 95%, and 100%.

41 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 2 -R 5 is selected from at least 25%, at least 50%, at least 75%, and 100%.

42 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 9 -R 16 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.

43 . A mixture of deuterium-enriched compound of claim 31 , wherein the abundance of deuterium in R 17 -R 24 is selected from at least 13%, at least 25%, at least 38%, at least 50%, at least 63%, at least 75%, at least 88%, and 100%.

44 . A mixture of deuterium-enriched compounds of claim 31 , wherein the compounds are selected from compounds 1-14 of Table 1:

45 . A mixture of deuterium-enriched compounds of claim 31 , wherein the compounds are selected from compounds 15-28 of Table 2:

46 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.

47 . A method for treating schizophrenia comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt form thereof.